S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)

Agenus Stock Forecast, Price & News

+0.16 (+5.54%)
(As of 01/14/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
3.83 million shs
Average Volume
3.57 million shs
Market Capitalization
$783.33 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive AGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for Agenus and its competitors with MarketBeat's FREE daily newsletter.

Agenus logo

About Agenus

Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 31, 1994 and is headquartered in Lexington, MA.


Agenus to Participate at Upcoming Investor Conferences
January 5, 2022 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$88.17 million
Book Value
($1.11) per share


Net Income
$-180.91 million
Pretax Margin




Free Float
Market Cap
$783.33 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.16 out of 5 stars

Medical Sector

434th out of 1,405 stocks

Biological Products, Except Diagnostic Industry

69th out of 206 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -

Agenus (NASDAQ:AGEN) Frequently Asked Questions

Is Agenus a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Agenus in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Agenus stock.
View analyst ratings for Agenus
or view top-rated stocks.

How has Agenus' stock price been impacted by Coronavirus (COVID-19)?

Agenus' stock was trading at $2.72 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, AGEN shares have increased by 12.1% and is now trading at $3.05.
View which stocks have been most impacted by COVID-19

Are investors shorting Agenus?

Agenus saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 24,620,000 shares, an increase of 31.9% from the December 15th total of 18,670,000 shares. Based on an average daily volume of 4,360,000 shares, the days-to-cover ratio is presently 5.6 days.
View Agenus' Short Interest

When is Agenus' next earnings date?

Agenus is scheduled to release its next quarterly earnings announcement on Monday, March 21st 2022.
View our earnings forecast for Agenus

How were Agenus' earnings last quarter?

Agenus Inc. (NASDAQ:AGEN) announced its quarterly earnings data on Tuesday, November, 9th. The biotechnology company reported $0.69 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.23. The biotechnology company earned $252.95 million during the quarter, compared to analysts' expectations of $183.11 million. During the same quarter in the prior year, the firm posted ($0.28) earnings per share.
View Agenus' earnings history

What price target have analysts set for AGEN?

2 brokerages have issued 1 year price objectives for Agenus' stock. Their forecasts range from $11.00 to $12.00. On average, they expect Agenus' share price to reach $11.50 in the next twelve months. This suggests a possible upside of 277.0% from the stock's current price.
View analysts' price targets for Agenus
or view top-rated stocks among Wall Street analysts.

Who are Agenus' key executives?

Agenus' management team includes the following people:

What is Garo H. Armen's approval rating as Agenus' CEO?

2 employees have rated Agenus CEO Garo H. Armen on Glassdoor.com. Garo H. Armen has an approval rating of 56% among Agenus' employees. This puts Garo H. Armen in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Agenus own?

What is Agenus' stock symbol?

Agenus trades on the NASDAQ under the ticker symbol "AGEN."

Who are Agenus' major shareholders?

Agenus' stock is owned by a number of retail and institutional investors. Top institutional investors include Diversified Trust Co (0.02%). Company insiders that own Agenus stock include Agenus Inc, Christine M Klaskin, Corp Incyte, Garo H Armen and Steven J O'day.
View institutional ownership trends for Agenus

Which major investors are buying Agenus stock?

AGEN stock was purchased by a variety of institutional investors in the last quarter, including Diversified Trust Co.
View insider buying and selling activity for Agenus
or or view top insider-buying stocks.

How do I buy shares of Agenus?

Shares of AGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Agenus' stock price today?

One share of AGEN stock can currently be purchased for approximately $3.05.

How much money does Agenus make?

Agenus has a market capitalization of $783.33 million and generates $88.17 million in revenue each year. The biotechnology company earns $-180.91 million in net income (profit) each year or ($0.12) on an earnings per share basis.

How many employees does Agenus have?

Agenus employs 359 workers across the globe.

What is Agenus' official website?

The official website for Agenus is agenusbio.com.

Where are Agenus' headquarters?

Agenus is headquartered at 3 FORBES ROAD, LEXINGTON MA, 02421.

How can I contact Agenus?

Agenus' mailing address is 3 FORBES ROAD, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at (781) 674-4400, via email at [email protected], or via fax at 781-674-4200.

This page was last updated on 1/17/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.